Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ BAX Stock Falls Following Q4 Earnings Miss, Margins Contract (Zacks) +++ BAXTER Aktie -3,91%

VANDA Aktie

 >VANDA Aktienkurs 
5.25 EUR    -16.0%    (TradegateBSX)
Ask: 5.25 EUR / 2900 Stück
Bid: 5.2 EUR / 3000 Stück
Tagesumsatz: 4058 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
VANDA Aktie über LYNX handeln
>VANDA Performance
1 Woche: -12,1%
1 Monat: -0,8%
3 Monate: +63,6%
6 Monate: +70,4%
1 Jahr: +34,6%
laufendes Jahr: -0,8%
>VANDA Aktie
Name:  VANDA PHARMACEUTICALS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US9216591084 / A0JJT3
Symbol/ Ticker:  VM4 (Frankfurt) / VNDA (NASDAQ)
Kürzel:  FRA:VM4, ETR:VM4, VM4:GR, NASDAQ:VNDA
Index:  -
Webseite:  https://www.vandapharma.c..
Profil:  Vanda Pharmaceuticals Inc. is a biopharmaceutical ..
>Volltext..
Marktkapitalisierung:  372.97 Mio. EUR
Unternehmenswert:  131.65 Mio. EUR
Umsatz:  178.22 Mio. EUR
EBITDA:  -95.02 Mio. EUR
Nettogewinn:  -70.76 Mio. EUR
Gewinn je Aktie:  -1.2 EUR
Schulden:  9.17 Mio. EUR
Liquide Mittel:  58.84 Mio. EUR
Operativer Cashflow:  -68.78 Mio. EUR
Bargeldquote:  2.49
Umsatzwachstum:  5.43%
Gewinnwachstum:  -387.5%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  VANDA
Letzte Datenerhebung:  12.02.26
>VANDA Kennzahlen
Aktien/ Unternehmen:
Aktien: 59.1 Mio. St.
Frei handelbar: 93.21%
Rückkaufquote: -
Mitarbeiter: 368
Umsatz/Mitarb.: 0.45 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 80.07%
Bewertung:
KGV: -
KGV lG: -
KUV: 2.17
KBV: 0.97
PEG-Ratio: -0.01
EV/EBITDA: -
Rentabilität:
Bruttomarge: 91.13%
Gewinnmarge: -39.7%
Operative Marge: -57.1%
Managementeffizenz:
Gesamtkaprendite: -13.51%
Eigenkaprendite: -16.72%
>VANDA Peer Group
Gesundheit
 
12.02.26 - 17:06
Vanda declines on Q4 results, weak 2026 revenue guidance (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
12.02.26 - 01:00
Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
 
Vanda (VNDA) delivered earnings and revenue surprises of +78.85% and -2.78%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?...
12.02.26 - 00:36
Vanda (VNDA) Q4 2025 Earnings Call Transcript (Fool)
 
Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...
11.02.26 - 23:49
Vanda Pharmaceuticals: Hoher Verlust in Q4 2025, Aktie dennoch im Plus (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
11.02.26 - 22:09
Vanda Pharmaceuticals GAAP EPS of -$2.39 misses by $1.07, revenue of $57.22M misses by $2.05M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
11.02.26 - 22:03
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results (PR Newswire)
 
Full year 2025 Fanapt® net product sales increased by 24% to $117.3 million compared to full year 2024 Full year 2025 total revenues increased by 9% to $216.1 million compared to full year 2024 NEREUS™ (tradipitant) approved for the prevention of vomiting induced by motion Bysanti™......
10.02.26 - 18:45
′Off The Charts′: Retail Is Buying-The-Dip In Software Stocks Like Never Before (ZeroHedge)
 
'Off The Charts': Retail Is Buying-The-Dip In Software Stocks Like Never Before Starting on Friday, we have seen a sudden reversal from panic-selling to panic-buying in tech stocks, which has lifted Nasdaq back above its 100DMA... The headline-grabbing culprit for much of the pain to the downside was Software stocks (IGV as an example of an ETF that tracks the sector), which collapsed as specifically SaaS firms faced 'existential threats' from AI disruption. That snapped Software valuations down dramatically... And, suddenly - starting Friday morning - buyers appeared to snap up these newly cheap stocks... Inflows into IGV - the Software ETF - have soared... But, the question has been - who's buying? Well now we have the answer, thanks to Vanda Research: 1M rolling net retail inflows into the iShares Software ETF (IGV) surged to a record $176mn as of close yesterday, more than double the prior peak seen during the late-2024 software drawdown. This is one of the more aggressive episodes o...
05.02.26 - 00:06
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 (PR Newswire)
 
Conference Call and Webcast to Follow WASHINGTON, Feb. 4, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2025 on Wednesday, February 11, 2026, after the market closes. Vanda will host a......
15.01.26 - 17:48
Levi & Korsinsky, LLP: Lost Money on Vanda Pharmaceuticals Inc. (VNDA)? Contact Levi & Korsinsky About Fraud Investigation (Newsfile)
 
New York, New York--(Newsfile Corp. - January 15, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") ......
15.01.26 - 16:03
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA (PR Newswire)
 
NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......
13.01.26 - 17:30
Vanda (VNDA) May Find a Bottom Soon, Here′s Why You Should Buy the Stock Now (Zacks)
 
After losing some value lately, a hammer chart pattern has been formed for Vanda (VNDA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term....
08.01.26 - 15:39
Vanda and Exante Data Combine in Strategic Merger (Business Wire)
 
Combined Business Offers a Unique Portfolio of Must-Have Data, Research and Analytical Solutions With Leading Capabilities in Tactical and Structural Flow and Positioning AnalysisLONDON & NEW YORK--(BUSINESS WIRE)--This morning Vanda, a global leader of high-frequency positioning data and tactical macro insights and Exante Data Inc, an innovative data analytics and global macro strategy provider announced they completed a definitive merger agreement. Under the terms of the agreement, Exante Data Inc will merge with and into Vanda through the acquisition by Vanda of all of the outstanding capital stock of Exante. Following the closing, Jens Nordvig will assume the role of President and join the Board of Directors of the combined company. Vanda is the market leader in tactical positioning and flow data, empowering a growing clientele which today includes the world's largest investment banks, hedge funds along with central banks, sovereign wealth funds and other leading global asset managers. Exante Data is...
08.01.26 - 14:42
Markets Strategist Nordvig Sells Firm, Will Join Merged Entity (Bloomberg)
 
Financial markets veteran Jens Nordvig — a top-ranked currency strategist for much of his career — is selling Exante Data Inc. to research firm Vanda and will become president of the combined company, he said....
08.01.26 - 13:51
Vanda falls as FDA rejects jet lag drug (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
08.01.26 - 13:36
FDA-Rückschlag für Vanda: Aktie stürzt nach abgelehnter Zulassung für Jetlag-Medikament ab (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
08.01.26 - 13:03
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder (PR Newswire)
 
WASHINGTON, Jan. 8, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has received a decision letter from the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) concluding that the supplemental New Drug......
01.01.26 - 10:12
Vanda Pharmaceuticals surges as FDA approves motion sickness drug (ShareCast)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
31.12.25 - 22:03
What′s Going On With Vanda Pharmaceuticals Stock Wednesday? (Benzinga)
 
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares are trading higher Wednesday after the company announced it received FDA approval of NEREUS for the prevention of vomiting induced by motion. read more...
31.12.25 - 15:15
VNDA Obtains FDA Nod for Motion Sickness Drug, Stock Gains (Zacks)
 
Vanda stock jumps after FDA approves tradipitant as Nereus for motion sickness, marking the first new therapy in over 40 years and boosting investor optimism....
31.12.25 - 14:30
FDA-Zulassung für Mittel gegen Reisekrankheit beflügelt Vanda-Aktie (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Mag alles Leid und Schatten sein - doch diese süße Sonnenstunde nicht, und nicht der Duft vom roten Klee, und nicht das tiefe, zarte Wohlgefühl in meiner Seele. - Hermann Hesse
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!